Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 5.25
High: 5.25
Low: 5.00
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 edges higher and New York stocks jump

Thu, 29th Dec 2022 16:52

(Alliance News) - London's FTSE 100 achieved a solid, though unspectacular, gain during the final full trading of the year on Thursday, with investors mindful of what an ease of Covid-19 curbs in China could mean for global inflation.

The FTSE 100 index ended up 15.53 points, or 0.2%, at 7,512.72. The FTSE 250 rose 110.95 points, or 0.6% at 18,996.45, and the AIM All-Share added 4.17 points, or 0.5%, at 836.45.

The Cboe UK 100 rose 0.1% at 750.88, the Cboe UK 250 added 0.6% at 16,459.77, and the Cboe Small Companies climbed 0.6% at 13,188.32.

The gains for London-listed large-caps were eclipsed by peers on the old continent and across the Atlantic.

In Europe, the CAC 40 index in Paris closed up 1.0%, while the DAX 40 in Frankfurt jumped 1.1%.

In New York, the Dow Jones Industrial Average was up 1.0% at the time of the closing bell in London, the S&P 500 was up 1.6% and the Nasdaq Composite jumped 2.4%.

Stocks in Paris, Frankfurt and New York had struggled on Wednesday.

Oanda analyst Craig Erlam commented: "We continue to drift into year-end with investors having little to cling onto that's going to drive markets one way or another. That is so often the case this time of year and while 2022 could have been different, given how chaotic the rest of the year has been, it has proven to not be the case. Investors are going into 2023 with a cautious mindset, prepared for more rate hikes, and expecting recessions around the globe. The bar is low but arguably reasonably so."

Investors worldwide initially welcomed the relaxation of Covid-19 restrictions in China, but they are now becoming increasingly concerned about the ramifications of the reopening of the Chinese economy for global supply chains and inflation.

Some nations have imposed restrictions on Chinese arrivals. The US and a number of other countries announced they would require negative Covid tests for all travellers from mainland China, though the UK so far has not.

However, the UK government appeared to backtrack on its suggestion that travellers from China will not be screened for Covid after critics, including two former health ministers, called for testing to be introduced.

Defence Secretary Ben Wallace said on Thursday that the possibility of imposing restrictions on visitors from the East Asian country was "under review".

It comes after former health ministers James Bethell and Steve Brine were among those to place pressure on the government following its assertion that there were "no plans" to introduce tests for China arrivals.

London-listed miners faced selling pressure on Thursday, having initially cheered the news out of China on Wednesday. China is a major buyer of minerals.

Anglo American fell 1.0%, while Antofagasta lost 2.1%.

Also hitting Antofagasta's stock, the miner reported that access to its Los Pelambres operation in Chile is being blocked by a group of people, affecting the transport of critical supplies and personnel to the mine site.

Antofagasta explained that the group is requesting compensation to clear access but added that, to date, there has been no material impact on production.

At the other end of the large-cap index, Scottish Mortgage Investment Trust rose 3.7%. The investor holds stakes in various US tech shares, which traded higher on Thursday.

Ferrexpo extended declines, losing 3.0% after a 4.9% drop on Wednesday. The iron ore pellet producer noted that Non-Executive Director Kostyantin Zhevago, who owns over 50% of the firm, has been detained by the French authorities.

Ferrexpo said that it believes this is for matters unrelated to the firm, but said it would week to clarify the situation and update as appropriate.

Applied Graphene extended gains. The AIM listing added a 34% rise to its 20% share price hike from Wednesday.

On Wednesday, it said it received non-binding indicative proposals for its sale or the sale of its main operating subsidiary.

The Cleveland, England-based graphene materials maker said it is in discussions with the parties involved and expects final proposals in early January. After this, the board would then select a preferred bidder to progress with. Applied added that there can be no certainty any final proposals will be made, nor the terms of any proposals made.

Allergy Therapeutics plunged 56% after it said its shares will be suspended from trading next week, due to delays in completing the audit of its annual results.

Back in September, Allergy Therapeutics announced its unaudited preliminary results for the financial year that ended June 30. It sunk to a pretax loss of GBP12.7 million from a profit of GBP3.7 million the year prior. Revenue dropped to GBP72.8 million from GBP84.3 million.

"It is not aware of any material change that will be required to be made to the results, and it is actively working to finalise the audit and publication of its annual report and accounts," Allergy Therapeutics said.

The pound was quoted at USD1.2057 at the time of the London equities close on Thursday, up compared to USD1.2029 at the close on Wednesday. The euro stood at USD1.0661, higher against USD1.0617. Against the yen, the dollar was trading at JPY133.31, lower compared to JPY134.23.

Brent oil was quoted at USD82.78 a barrel in London on Thursday, down slightly from USD82.87 late Wednesday. Gold was quoted at USD1,811.91 an ounce, higher against USD1,801.04.

Friday's economic calendar has a UK Nationwide house price index reading at 0700 GMT. Financial markets in London will close early at 1230 GMT on Friday.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
29 Sep 2016 11:55

DIRECTOR DEALINGS: Allergy Therapeutics Chairman Lifts Stake

Read more
28 Sep 2016 10:41

DIRECTOR DEALINGS: Allergy Therapeutics Finance Boss Buys First Shares

Read more
26 Sep 2016 14:24

Allergy Therapeutics swings to FY loss on R&D spend

(ShareCast News) - Allergy Therapeutics posted a rise in revenue for the year to the end of June but said it swung to a loss as it ramped up its spending on research and development. Revenue rose 12% from 2015 to £48.5m but the company reported a pre-tax loss of £12.1m versus a profit of £654,000 th

Read more
26 Sep 2016 09:46

Numis reiterates 'buy' on Allergy Therapeutics after full year results

(ShareCast News) - Numis reiterated a 'buy' rating and target price of 37p on Allergy Therapeutics on Monday after the company reported its full year results. Allergy reported a 19% increase in revenue at constant currency to £51.5m in the year ended 30 June as it grew market share in its main Europ

Read more
13 Jul 2016 08:43

Allergy Therapeutics Expects Revenue Rise Despite Euro Weakening

Read more
8 Jul 2016 14:02

Allergy Therapeutics sees good results from Acarovac Plus

(ShareCast News) - Specialty pharmaceutical company Allergy Therapeutics published a one-year follow up study of patients using Acarovac Plus on Friday, in the peer-review journal Immunotherapy. The AIM-traded firm's Acarovac Plus product was described as a microcrystalline tyrosine-adsorbed, house

Read more
8 Jul 2016 07:26

Allergy Therapeutics Welcomes Positive Follow-Up Results For Acarovac

Read more
27 Jun 2016 09:51

WINNERS & LOSERS SUMMARY: easyJet And Foxtons In Post-Brexit Warnings

Read more
27 Jun 2016 09:06

Allergy Therapeutics Sees Delayed US Market Launch For GrassMATAMPL

Read more
10 Jun 2016 07:41

Allergy Therapeutics Appoints Skyepharma's Wykeman As Finance Director

Read more
9 May 2016 06:57

Allergy Therapeutics Gets Positive Birch Pollen Treatment Results

Read more
5 Apr 2016 08:12

NetScientic Poaches New Finance Boss From Allergy Therapeutics

Read more
17 Mar 2016 09:08

Allergy Therapeutics Finance Director Ian Postlethwaite Resigns

Read more
10 Mar 2016 09:33

BROKER RATINGS SUMMARY: Jefferies Starts Metro Bank With Buy Rating

Read more
8 Mar 2016 10:59

Allergy Therapeutics Profit Drops On Higher Costs As Revenue Edges Up

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.